ZHEJIANG MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.53 CNY | +0.42% |
|
+2.47% | -11.18% |
| 25/04 | Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 2023 | Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug | MT |
| Sales 2024 * | 8.62B 1.19B 99.23B | Sales 2025 * | 9.41B 1.3B 108B | Capitalization | 9.13B 1.26B 105B |
|---|---|---|---|---|---|
| Net income 2024 * | 467M 64.48M 5.38B | Net income 2025 * | 636M 87.81M 7.32B | EV / Sales 2024 * | 1.06 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.97 x |
| P/E ratio 2024 * |
19.9
x | P/E ratio 2025 * |
14.4
x | Employees | 6,208 |
| Yield 2024 * |
1.57% | Yield 2025 * |
2.1% | Free-Float | 58.61% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.42% | ||
| 1 week | +2.47% | ||
| Current month | +6.60% | ||
| 1 month | +6.24% | ||
| 3 months | -2.66% | ||
| 6 months | -8.89% | ||
| Current year | -11.18% |
1 week
8.96
9.57
1 month
8.959.86
Current year
7.9710.98
1 year
7.9712.11
3 years
7.9721.16
5 years
7.9722.31
10 years
7.8122.31
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Lei Lu
CEO | Chief Executive Officer | 57 | 01/06/01 |
Nan Xing Li
BRD | Director/Board Member | 38 | 11/15/11 |
Ke Qiu
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Bo Li
CHM | Chairman | 65 | 01/97/01 |
Nai Wei Chen
BRD | Director/Board Member | 67 | 15/18/15 |
Chun Lei Lu
CEO | Chief Executive Officer | 57 | 01/06/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 31 M€ | +3.50% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 9.53 | +0.42% | 17,511,720 |
| 25/24/25 | 9.49 | +3.72% | 20,727,880 |
| 24/24/24 | 9.15 | 0.00% | 10,228,010 |
| 23/24/23 | 9.15 | -0.87% | 10,533,270 |
| 22/24/22 | 9.23 | -0.75% | 11,598,570 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
23/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.53
CNY
Average target price
11
CNY
Spread / Average Target
+15.42%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.18% | 1.26B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600216 Stock
